A Phase 1 Dose Escalation Study of ARQ 197 Administered in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 15 Apr 2014
At a glance
- Drugs Gemcitabine; Tivantinib
- Indications Solid tumours
- Focus Adverse reactions
- 18 Oct 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 18 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.